The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...

MADISON, N.J., September 17, 2024--(BUSINESS WIRE)--LEO Pharma Inc. announced today the availability of the Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States.

The new single-dose autoinjector is available in a 300mg/2mL dosage strength and is intended for use in adults only. The Food and Drug Administration (FDA) has approved a new single-dose ...

In the United States, it is marketed as Adbry and is available in the 150 mg dose pre-filled syringe. The new device has a hidden needle and a press-down auto-injection feature. The 2 ml syringe ...

Single-dose autoinjector will provide adult patients in the U.S. with an alternative method of administration for Adbry, with the device planned to be available in the coming months. The ...

The pre-filled pen, developed in partnership with a global leader in innovative injection systems, features a hidden needle and a simple ... under the tradename Adbry ® and is approved for ...

Please provide your email address to receive an email when new articles are posted on . Adbry is now available in the U.S. as a 300 mg/2 mL single-dose autoinjector for adults with atopic dermatitis.